Insider Selling: Phreesia, Inc. (NYSE:PHR) General Counsel Sells 3,982 Shares of Stock

Phreesia, Inc. (NYSE:PHR) General Counsel Allison C. Hoffman sold 3,982 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $26.61, for a total transaction of $105,961.02. Following the completion of the transaction, the general counsel now directly owns 159,137 shares of the company’s stock, valued at $4,234,635.57. This trade represents a 2.44 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Phreesia Price Performance

NYSE PHR opened at $26.75 on Friday. The stock’s fifty day moving average price is $22.87 and its 200 day moving average price is $22.62. Phreesia, Inc. has a 1 year low of $17.07 and a 1 year high of $29.16. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.74 and a quick ratio of 1.77. The company has a market cap of $1.55 billion, a price-to-earnings ratio of -18.20 and a beta of 0.94.

Phreesia (NYSE:PHR) last announced its quarterly earnings data on Monday, December 9th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.04. The firm had revenue of $106.80 million during the quarter, compared to analysts’ expectations of $106.33 million. Phreesia had a negative return on equity of 32.78% and a negative net margin of 20.43%. The company’s revenue for the quarter was up 16.6% compared to the same quarter last year. During the same period last year, the business posted ($0.58) earnings per share. As a group, equities research analysts forecast that Phreesia, Inc. will post -1.16 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on PHR shares. Citigroup upped their price objective on Phreesia from $31.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday. Royal Bank of Canada raised shares of Phreesia from a “sector perform” rating to an “outperform” rating and increased their price target for the company from $24.00 to $32.00 in a research report on Wednesday. Robert W. Baird cut their price objective on shares of Phreesia from $34.00 to $30.00 and set an “outperform” rating on the stock in a research report on Wednesday, December 11th. Needham & Company LLC reissued a “buy” rating and set a $29.00 target price on shares of Phreesia in a research report on Friday. Finally, KeyCorp lifted their price target on shares of Phreesia from $28.00 to $30.00 and gave the stock an “overweight” rating in a report on Wednesday. Twelve research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $31.00.

Institutional Trading of Phreesia

Several institutional investors and hedge funds have recently bought and sold shares of the business. Franklin Resources Inc. lifted its position in Phreesia by 3.0% during the third quarter. Franklin Resources Inc. now owns 1,497,631 shares of the company’s stock valued at $31,495,000 after purchasing an additional 42,973 shares during the period. Geode Capital Management LLC raised its stake in shares of Phreesia by 4.7% during the 3rd quarter. Geode Capital Management LLC now owns 1,245,797 shares of the company’s stock valued at $28,397,000 after buying an additional 55,934 shares during the last quarter. M&T Bank Corp lifted its holdings in shares of Phreesia by 4.6% in the 3rd quarter. M&T Bank Corp now owns 35,127 shares of the company’s stock valued at $801,000 after buying an additional 1,535 shares during the period. Barclays PLC boosted its stake in shares of Phreesia by 83.6% in the third quarter. Barclays PLC now owns 94,929 shares of the company’s stock worth $2,163,000 after buying an additional 43,225 shares during the last quarter. Finally, XTX Topco Ltd purchased a new stake in shares of Phreesia in the third quarter worth about $247,000. 92.10% of the stock is currently owned by institutional investors and hedge funds.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.